# A Randomized, Active-controlled, Parallel, Open-label, Multicenter, Phase 4 Study to Compare the Efficacy and Safety of Pregabalin Sustained Release Tablet and Pregabalin Immediate Release Capsule in Type II Diabetic Patients With Peripheral Neuropathic Pain

> **NCT05624853** · PHASE4 · COMPLETED · sponsor: **Yuhan Corporation** · enrollment: 130 (actual)

## Conditions studied

- Neuropathic Pain
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** pregabalin sustained release tablet
- **DRUG:** pregabalin immediate release capsule

## Key facts

- **NCT ID:** NCT05624853
- **Lead sponsor:** Yuhan Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-12
- **Primary completion:** 2022-12-20
- **Final completion:** 2022-12-20
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2023-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05624853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05624853, "A Randomized, Active-controlled, Parallel, Open-label, Multicenter, Phase 4 Study to Compare the Efficacy and Safety of Pregabalin Sustained Release Tablet and Pregabalin Immediate Release Capsule in Type II Diabetic Patients With Peripheral Neuropathic Pain". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT05624853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*